The IFN-γ-related inflammatory status in MAS/HLH patients may need to be considered in relation to CXCL9, but whether the timing of emapalumab administration should be determined based on CXCL9 requires further validation through clinical trials. This evidence concerns the gene IFNG and hemophagocytic syndrome.